Articles tagged with Crisprs
Researchers at IBS have identified the mistake-rate of DNA editing tools using CRISPR and adenine base editors. The study reveals that ABE7.10, a widely used gene engineering tool, has an average of 60 off-target mistakes in the human genome.
The CRISPR Journal announces publication of its February 2019 issue, featuring studies on strain tracking, single-step genome editing, and chromatin modulating motifs. Researchers discuss advancements in CRISPR technology and its applications.
A new CMP-fusion strategy called CRISPR-chrom enhances CRISPR-Cas9 genome editing efficiency, especially at previously difficult-to-target sites. The approach demonstrates a substantial increase in CRISPR-Cas9 activity with no notable increase in off-target effects.
Researchers at Duke University found that a single CRISPR treatment can safely correct genetic disease for over a year, despite immune responses. The study suggests approaches to address potential challenges and potentially deliver the therapy to infants or restrict Cas9 expression.
Researchers at IDIBELL have developed Nested CRISPR, a cloning-free method for genome editing using long DNA fragments. The technique involves two steps: inserting a small portion of the fragment into the genome and then using it as a
Researchers have developed two molecular safeguards to prevent accidental spread of CRISPR gene drives in the lab. Synthetic target site drive and split drive strategies show similar performance to standard drives, making them suitable substitutes for early gene-drive research.
A research team has identified and overcome a barrier in CRISPR gene editing that may lay the foundation for sustained treatments using the technique. By increasing the quantity of 'flags' in CRISPR, they were able to extend the effectiveness of treatment from three months to 18 months in mice with Duchenne muscular dystrophy.
The CRISPR Journal publishes outstanding research on all aspects of CRISPR and gene editing. Two new articles explore the ethics of germline editing and the use of alternative PAM sequences for mouse genome editing.
A team of UD engineers has developed a method to use CRISPR/Cas9 technology for conditional gene regulation, introducing a new functionality to the technology. This allows scientists to precisely target and edit DNA within living cells, which could help correct inherited diseases.
Researchers at UCSF developed CRISPRa, a modified version of the gene-editing tool that activates appetite-suppressing genes without making cuts to the genome. This approach prevented severe obesity in genetically engineered mice with only one functional copy of certain genes.
Researchers at the Francis Crick Institute discovered simple rules that determine the precision of CRISPR/Cas9 genome editing in human cells. By analyzing hundreds of edits, they found predictable patterns behind the technology, allowing for greater precision and efficiency.
Researchers have developed a deeper understanding of the CRISPR-Cas12a mechanism, enabling fine-tuning of the gene-editing process. By mapping the molecular structure and sequence of events, scientists can optimize the technology to achieve desired effects while minimizing side effects.
The CRISPR genome editing technique is revolutionizing plastic and reconstructive surgery with potential advances in craniofacial malformations, therapeutic skin grafts, and rejection-free transplants. Many challenges remain, including off-target effects, FDA regulation, and high costs.
Researchers have developed a new Cas9 enzyme that can target almost half of the genome's locations, significantly expanding its potential use. This could enable editing of many more disease-specific mutations, including those responsible for sickle cell anemia.
Researchers developed a novel technology to analyze hundreds of genes at single cell level, revealing critical immune system weakness in cancer. The Pro-Code technique identified disease-causing genes and potential drug targets for cancer immunotherapy.
The CRISPR Journal has published new articles on the development of a novel transcriptional activator system, CRISPR-Cas classification, patent appeals, anti-CRISPR proteins, and CRISPR-based art. Researchers have made significant advancements in understanding the complexities of CRISPR biology.
Researchers found a compact CRISPR gene-editing machinery in ancient microbes, dubbed Cas14, which is smaller than other Cas proteins and has the potential to improve rapid diagnostic systems for infectious diseases, genetic mutations, and cancer. The discovery of Cas14 could provide a powerful addition to diagnostic tools.
A multidisciplinary team applies CRISPR on a human liver-on-a-chip platform to identify biomarkers for toxicity and off-target effects. The study aims to predict liver tissue response in humans and develop effective gene editing tools.
Researchers at the Institute of Molecular Pathology Biomarkers at the University of Extremadura have discovered a new biomarker for Alzheimer's disease of sporadic origin, protein STIM1. A deficiency in this protein has been linked to calcium ion transport abnormalities, which can lead to neurodegeneration and cell death.
Researchers use CRISPR to tame the wild groundcherry, increasing fruit size and weight, and reducing weed growth habit. The modified plant also exhibits fewer instances of fruit drop, addressing food safety concerns.
Researchers at the Salk Institute have discovered the molecular structure of CRISPR-Cas13d, a promising enzyme for emerging RNA-editing technology. This breakthrough enables scientists to visualize how the enzyme guides and targets RNA, paving the way for new strategies to treat RNA-based diseases.
Researchers at UT Southwestern Medical Center used CRISPR genome-wide screening to identify the IFI6 gene as a potent antiviral gene targeting flaviviruses, including West Nile and Zika viruses. The study found that cells with a working IFI6 gene inhibited infection by these viruses in cell culture studies.
Researchers used CRISPR gene editing to restore dystrophin protein levels by up to 92% in dogs with Duchenne muscular dystrophy. The study provides strong indication of a potential lifesaving treatment for the disease, which affects one in 5,000 boys and leads to muscle and heart failure.
The CRISPR Journal publishes groundbreaking research on gene editing, including off-target effects in HIV therapy and the role of p53 in genome editing. The journal explores the ethics of CRISPR technology and its potential applications.
Researchers found that Cas12a is a more choosier enzyme than Cas9 due to its binding mechanism, making it less likely to edit the wrong part of the genome. This discovery could lead to improved gene editing in plants and animals with increased safety for human applications.
Researchers discovered that the Fanconi anemia DNA repair pathway plays a crucial role in fixing CRISPR breaks and increasing the efficiency of homology-directed repair. This new understanding could help boost CRISPR-Cas9 editing's success rates, particularly for treating diseases like sickle cell anemia.
Researchers discovered that phages cooperate to rapidly infect bacteria, overcoming destruction by CRISPR. The cooperation allows the first phage to sacrifice itself and produce anti-CRISPR compounds to neutralize some CRISPs, helping subsequent phages. This new model proposes a tipping point between numbers and speed of CRISPR and ant...
Recent studies have raised safety concerns over CRISPR's precision in human cell lines, but companies are forging ahead with therapies. The technology makes double-stranded breaks at specific sites in DNA to repair defective genes.
Researchers at University of California - San Francisco have successfully genetically reprogrammed human immune cells known as T cells without the need for viruses to insert DNA. The new CRISPR-based method employs electroporation and offers a robust molecular 'cut and paste' system to rewrite genome sequences in human T cells.
Researchers at University of Illinois Chicago discovered that persistent binding of the Cas9 protein to DNA causes CRISPR failure. To improve efficiency, they found that consistent strand selection forces RNA polymerases to collide with Cas9, knocking it off DNA.
The CRISPR Journal announces its third issue with novel techniques for long DNA delivery, correction of recessive genetic defects using endogenous repair, base editing quantification software, leveling the CRISPR playing field through accessible plasmid repositories, and insights into CRISPR's future by Editor-in-Chief Rodolphe Barrangou
Addgene has made over 100,000 CRISPR plasmids available to laboratories worldwide, democratizing genome editing research. This global access has enabled the advancement and flourishing of CRISPR technology.
Researchers have developed a simpler and faster CRISPR method that allows for off-the-shelf genome engineering, reducing the barrier to entry for this powerful technology. The approach targets universal sequences found in gene knockout collections, enabling rapid single nucleotide editing and generating chromosomal mutant collections.
Researchers have developed a CRISPR-based treatment that can restore retinal function in mice afflicted with retinitis pigmentosa, a degenerative eye disease. The 'ablate-and-replace' strategy allows for the precise removal and replacement of the faulty gene, enabling faster and less expensive treatment options for dominant disorders.
Researchers used CRISPR-Cas9 to introduce genetic mutations into cacao plants, resulting in enhanced disease resistance. The study suggests that a fraction of the targeted gene's copies may be sufficient to trigger systemic disease resistance.
Researchers developed MAGESTIC to refine gene-editing process, enhancing precision and increasing cell survival rates by sevenfold. The new platform enables precise editing of genetic variants, helping uncover impact on cellular function and disease susceptibility.
Researchers at Stanford University School of Medicine successfully used CRISPR-Cas9 to genetically edit coral, demonstrating its potential as a resource for coral biologists. The technique allowed them to identify critical genes in coral biology and alter multiple gene copies, offering hope for conserving coral reefs.
The CRISPR Journal publishes new research on cell-free CRISPR systems, which enable the study of gene editing mechanisms in a defined manner. Additionally, a universal CRISPR activity model called TUSCAN has been developed to predict CRISPR-Cas9 activity and genome-wide screening tasks.
Scientists at Christiana Care's Gene Editing Institute have developed a breakthrough CRISPR tool that can edit DNA in a test tube, allowing for precise genetic mutations to be replicated from human tumor samples. This technology has the potential to accelerate personalized cancer care by enabling rapid diagnosis and treatment.
A new bioinformatics tool, CRISPRdisco, has been developed to identify and classify CRISPR-Cas systems in genome assemblies. The software detects CRISPR repeats and accurately assigns class, type, and subtypes, enabling researchers to distinguish between complete and incomplete CRISPR systems.
New gene editing regulations could hinder the use of CRISPR technology in food animals, potentially limiting disease resistance and beneficial traits. The FDA's proposal would impose drug-like regulatory scrutiny, but experts suggest alternative routes to approval that could accelerate benefits from conventional breeding.
Scientists have developed a new CRISPR method to analyze the effects of thousands of gene edits in parallel, improving their ability to identify harmful genetic changes. This technique enables researchers to rapidly distinguish between damaging and harmless edits, potentially leading to breakthroughs in disease diagnosis and treatment.
The CRISPR Journal has published new research on gene editing regulations, introducing potential global implications for food animal production. A bioinformatic pipeline, dubbed CRISPRdisco, has been developed to help researchers identify and characterize CRISPR repeats and genes encoding Cas nucleases.
Researchers have used CRISPR gene editing to introduce beneficial natural mutations into blood cells, boosting their production of foetal haemoglobin. This approach may lead to new therapies for sickle cell anaemia and thalassaemia by targeting precise changes in the genome.
Salk Institute scientists have developed a CRISPR-based tool called CasRx that targets RNA to correct protein imbalances in cells from dementia patients. The tool showed 80% effectiveness in rebalancing tau protein levels, opening up new avenues for treating RNA and protein-related diseases.
Researchers at Ohio State University have discovered a new CRISPR mechanism that can help prevent gene-editing errors. The discovery reveals how the Cas9 enzyme determines where and when to cut DNA strands, allowing for more precise control over gene editing.
The inaugural issue of The CRISPR Journal features a range of articles on CRISPR biology, technology, and genome editing. Research highlights include progress in treating genetic diseases, such as hereditary blindness and Batten disease, using CRISPR-Cas9 gene editing.
Researchers at the University of Michigan have discovered a new CRISPR-Cas9 protein, NmeCas9, that can edit both DNA and RNA with high precision. This breakthrough could lead to new therapeutic possibilities for diseases caused by genetic mutations in RNA.
The CRISPR Journal debuts with original research papers on plant editing, gene drives, and therapeutic applications. Researchers make progress in targeting specific mutations for inherited diseases like retinitis pigmentosa.
Researchers have developed a CRISPR-based method, DETECTR, to detect viral DNA, including cancer-causing HPV types. The system uses a molecular flare gun to identify specific DNA targets, enabling fast and reliable medical tests with minimal equipment requirements.
Scientists developed a CRISPR gene-editing technique that can correct most DMD mutations by making a single cut at strategic points along the patient's DNA. The new strategy enhances genome editing accuracy and offers an efficient alternative to individualized molecular treatments.
Researchers at Gladstone Institutes have successfully created induced pluripotent stem cells using CRISPR technology, simplifying a key step in the process. This breakthrough offers new possibilities for treating currently incurable conditions and studying diseases.
Three companies - Crispr Therapeutics, Intellia Therapeutics, and Editas Medicine - are launching clinical trials using CRISPR to boost healthy hemoglobin levels in patients with blood diseases. Researchers are also conducting extensive computer predictions and in vitro tests to minimize the risk of accidents.
Researchers at Columbia University Irving Medical Center have developed a microscopic data recorder using CRISPR-Cas technology, allowing bacteria to monitor their surroundings and record temporal changes. The system has proven its ability to handle multiple signals and record for days.
A new nanomapping technology combines high-speed atomic force microscopy with a CRISPR-based chemical barcoding technique to map DNA nearly as accurately as DNA sequencing. The technology can process large sections of the genome at a much faster rate, using parts found in DVD players.
Researchers at UCR have developed transgenic mosquitoes stably expressing the Cas9 enzyme, enabling efficient genome editing to disrupt genes controlling vision, flight, and feeding. The long-term goal is to use these mosquitoes with gene drives to insert genes that suppress disease-spreading insects.
Researchers at MIT have created a new delivery system for the CRISPR genome-editing system, using nanoparticles to target and delete disease-causing genes. The technique achieved an 80% success rate in deleting the Pcsk9 gene, which regulates cholesterol levels, resulting in a 35% drop in total cholesterol levels.
Scientists have developed a new CRISPR RNA editing tool called REPAIR, which can target and edit RNA with high efficiency and specificity. This tool allows for the correction of mutations in different time windows, including during key developmental periods, and may have disease-modifying potential.
Experts discuss the potential risks and benefits of gene editing, including its applications in human health, agriculture, and the environment. The discussion highlights the need for harmonized policies across national borders to address concerns about misuse and unintended consequences.
Researchers created a computational model to improve the efficiency of CRISPR-Cas9 genome editing by allowing off-target cuts, which may help on-target cutting be faster. The model suggests that proteins can correct mistakes and tolerate minor mutations, potentially leading to more precise gene editing.